Pincus & Co. Warburg

Director Pincus & Co. Warburg sells entire 19,102,952 share stake in SHC for $289.8M at $15.17; stock down 4.7% in 30 days, -23.1% from 52-week high.

Pincus & Co. Warburg liquidated his complete position in Sotera Health—19,102,952 shares for $289,753,575.94 total value—on 2026-05-13, leaving zero post-transaction holdings. The sale occurred at $15.17 while the stock has since declined to $15.27 (current price is -23.1% from its 52-week high of $19.85) and has fallen 4.7% in the 30 days since the transaction. Across his prior five trades specifically at SHC, Pincus achieved well-timed exits on 2 of 5 occasions (measured by negative 90-day returns post-sale). The complete exit warrants investor attention given the large absolute dollar value and the concentration risk this insider was previously carrying.

Warburg Pincus & Co. exits SHC entirely, selling 19,102,952 shares at $15.17 for $289,753,575.94, reducing stake to 0.

Warburg Pincus & Co. (Director) sold its entire position of 19,102,952 shares of Sotera Health Co (SHC) at $15.17 on 2026-05-13 for total proceeds of $289,753,575.94, leaving 0 shares post-transaction — a complete exit from the company. This sale occurred with SHC trading -23.1% below its 52-week high of $19.85, and the stock has declined -4.7% over the prior 30 days and -10.8% over the prior 90 days. Across Warburg Pincus & Co.'s cross-ticker sell history, the 90-day well-timed rate stands at 50.00%, and prior sells at SHC specifically showed mixed outcomes: the March 2026 sells produced a 30-day return of -2.0% and a 90-day return of +1.4%, while the December 2025 sells showed a 30-day return of +8.3% and a 90-day return of -3.9%. The complete liquidation of a 19.10M share position by a Director-level holder is a material ownership event regardless of prior timing patterns, and investors should note that SHC trades at a P/E of 37.24 against a market cap of $4.4B with quarterly net income of $26,589,000.

Warburg Pincus sells 15,000,000 SHC shares for $229.0M at $15.27; exits -44.0% of position as stock trades -27.3% from 52-week high

Warburg Pincus substantially reduced its SHC position by 15,000,000 shares (44.0% of prior holdings) on 2026-03-06 at $15.27 per share, generating $229,050,000.00 in proceeds. The timing is notable: the sale occurred when the stock was -27.3% below its 52-week high and has declined -20.8% in the 30 days since the transaction and -16.8% over 90 days. Across his prior SHC trades (5 prior transactions), 2 of 4 measurable historical sales showed negative 90-day returns after sale (well-timed outcomes), though the other 2 showed positive returns. The current price of $14.06 sits 7.9% below the execution price, partially validating this exit point relative to recent momentum. At a P/E of 45.35 and 5.7% annual revenue growth, the company commands a premium valuation that may weigh on near-term upside.

Warburg Pincus (Director) sells 15.00M SHC shares at $15.27; holdings drop 44.0% to 19.10M shares as stock falls -27.3% from 52-week high.

Warburg Pincus sold 15,000,000 shares of Sotera Health on 2026-03-06 at $15.27, reducing its stake by -44.0% from 34,102,952 to 19,102,952 shares, representing a $229,050,000.00 reduction in holdings. The stock has declined to $14.06, now -27.3% from its 52-week high of $19.35, with a -20.8% drop over 30 days and -16.8% over 90 days, suggesting the market has repriced the company post-transaction. At the same ticker, Warburg Pincus' prior four measurable sales showed mixed timing: 2 of 4 were well-timed at the 90-day mark (2025-11-10 sales both showed +7.9% at 30d and +13.4% at 90d, indicating the stock rose after those sales), while 2 of 4 were poorly timed (2025-12-03 sales both returned +8.3% at 30d but -3.9% at 90d). The current transaction's large scale and the stock's sharp subsequent decline warrant monitoring to assess whether this sale signals a change in confidence or market conditions at Sotera Health.

WARBURG PINCUS & CO. sells 9,720,000 shares of SHC at $16.33; holdings drop to 34.10M (-22.2%)

WARBURG PINCUS & CO. executed a substantial sale of 9,720,000 shares at $16.33 on 2025-12-03, reducing its stake from 43,822,952 to 34,102,952 shares and cutting holdings by 22.2%. The transaction was completed at $16.33, which is near the current price of $16.75 and well within the 52-week range of $9.80–$17.48 (within 4.2% of the 52-week high). At the same-ticker level, the insider's prior two measurable sales at SHC (both on 2025-09-05) saw the stock subsequently post positive 90-day returns of +9.6%, indicating those earlier exits were not well-timed. The cross-ticker track record shows a 66.67% well-timed rate on 9 prior sells, though that metric does not predict performance at this specific ticker. Given the substantial reduction in holdings, near-peak pricing at transaction time, and the company's elevated P/E of 83.75 against modest revenue growth of 4.9%, the transaction merits investor attention but remains within normal portfolio management parameters.

Warburg Pincus sells 9,720,000 SHC shares for $158.7M; holdings drop 22.2% to 34.10M

Warburg Pincus (Director) executed a substantial sale of 9,720,000 shares at $16.33 on 2025-12-03, reducing holdings by 22.2% to 34,102,952 shares and generating $158,727,600.00 in proceeds. This represents a meaningful reduction in the director's position at Sotera Health, which trades near its 52-week high of $17.48 at a current price of $16.75. The transaction occurs at a valuation where the company's P/E of 83.75 and recent quarterly revenue of $311,312,000.00 with net income of $48,400,000.00 merit scrutiny; the director's multi-transaction history at SHC shows that 0 of 2 prior measurable sells were well-timed (stock rose 9.6% over 90 days following the September sells), suggesting the insider's exits at this ticker have not anticipated subsequent declines. Investors should monitor whether this large exit—combined with the company's rich valuation and modest 4.9% annual revenue growth—reflects evolving confidence in the equity or is driven by other portfolio considerations.

Warburg Pincus sold 18,000,000 shares of SHC at $15.65 for $281.7M, reducing stake by 29.1%

Warburg Pincus executed a substantial $281.7M divestiture of 18,000,000 shares, reducing its SHC holding from 61.82M to 43.82M shares (a 29.1% reduction). This represents a meaningful reduction in the insider's position size at a price of $15.65, which sits 3.8% below the 52-week high of $16.90. The sale's significance is underscored by the insider's track record across all tickers: its 7 prior open-market sells showed a 100.00% well-timed rate at the 90-day mark, and at SHC specifically, 2 of 2 prior sales were well-timed at 90 days. However, current context matters—the stock has appreciated 3.7% over 30 days and 3.1% over 90 days, and trades at a P/E of 81.25 against annual revenue growth of 4.9%, suggesting elevated valuation multiples relative to growth. Investors should monitor whether this large, multi-year stake reduction signals confidence in near-term valuations or a fundamental reassessment of the company's outlook.

Warburg Pincus & Co. sold 18,000,000 shares of Sotera Health at $15.65, reducing holdings by -29.1%, raising $281.7M

Warburg Pincus & Co. executed a major capital reduction at Sotera Health, divesting 18,000,000 shares (-29.1% of pre-transaction holdings) for $281,718,000.00. The sale occurred at $15.65, trading 3.8% below the 52-week high of $16.90, near the upper end of the 52-week range. Across his open-market history, this insider's prior sales exhibited a 90-day well-timed rate of 100.00%, and at this specific ticker, 2 of 2 prior measurable 90-day outcomes from sales yielded declines (-13.7% in both cases). The company trades at a P/E of 81.25 on quarterly revenue of $311,312,000.00 and net income of $48,400,000.00, with modest annual growth of +4.9%. The execution of a large block sale by a significant shareholder represents a material portfolio action that may reflect capital deployment priorities rather than confidence in near-term equity appreciation at current valuation levels.

Warburg Pincus sells 12.00M SHC shares at $15.11, reducing stake 16.3% to 61.82M; prior 4 sales at this ticker 100% well-timed at 90-day mark

Warburg Pincus sold 12,000,000 shares of Sotera Health on 2025-09-05 at $15.11, a material 16.3% reduction in holdings to 61,822,952 shares, representing $181,332,000 in transaction value. This transaction is noteworthy because the insider's prior 4 measurable sales at the same ticker (2024-09-06 and 2024-03-04) were all well-timed at the 90-day mark, with negative returns of -13.7% and -21.9% respectively—consistent with a pattern of selling before declines. Additionally, across his broader cross-ticker portfolio, Warburg Pincus achieved a 100.00% well-timed rate on 5 prior sells, suggesting consistent ability to exit positions ahead of unfavorable price action. The current stock price of $15.81 sits -6.5% from the 52-week high, and the 30-day momentum is strong at +13.2%, yet the historical pattern at this ticker signals that the insider may be exiting ahead of further weakness that would emerge over the 90-day window.

Warburg Pincus sells 12,000,000 SHC shares for $181.3M; holds 61.82M shares; 4 of 4 prior sells at this ticker fell 90-days later.

Warburg Pincus (Director) divested 12,000,000 shares of Sotera Health at $15.11 on 2025-09-05, reducing holdings from 73.82M to 61.82M shares (-16.3%). This sale is noteworthy given the insider's prior trading pattern at SHC: all 4 measurable historical sales (2024-09-06 and 2024-03-04) were followed by 90-day declines of -13.7% and -21.9% respectively, a 100% accuracy rate in preceding downturns. The current stock price of $15.81 sits just 4.6% above the transaction price and has rebounded 31.1% over 90 days from prior lows, meaning the timing utility of this sale cannot yet be assessed. At a P/E of 197.62 and net income of only $8.0M on revenue of $294.3M, the company carries an elevated valuation multiple relative to profitability, which may frame investor concerns about sustainability. The scale of this divestiture—a $181.3M transaction representing significant position reduction—and the director's demonstrated pattern of selling ahead of subsequent declines should prompt monitoring of the 90-day forward price action.